4'-Methoxy-α-pyrrolidinopropiophenone
Clinical data
Routes of
administration		By mouth, insufflation, vaporization, IV
Legal status
Legal status
Identifiers
  • (RS)-1-(4-Methoxyphenyl)-2-(1-pyrrolidinyl)-1-propanone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC14H19NO2
Molar mass233.311 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • C2CCCN2C(C)C(=O)c(cc1)ccc1OC
  • InChI=1S/C14H19NO2/c1-11(15-9-3-4-10-15)14(16)12-5-7-13(17-2)8-6-12/h5-8,11H,3-4,9-10H2,1-2H3
  • Key:QJWOQBGBEFNYKB-UHFFFAOYSA-N

4'-Methoxy-α-pyrrolidinopropiophenone (MOPPP) is a stimulant designer drug of the pyrrolidinophenone class. It has the potential to produce euphoria, an effect shared with other classical stimulants.

Recreational use

MOPPP use is infrequent when compared to other amphetamines or stimulants used recreationally, such as meth, cocaine, or speed. It first arose as a designer drug in Germany in the late 1990s and early 2000s,[1][2][3] along with a number of other derivatives but never gained the international popularity[4][5] that other drugs in its family of pyrrolidinophenone derivatives had (such as α-PPP and MDPV).

While the recent trend of selling stimulants through false labeling (i.e., bath salts) has gained notoriety, using MDPV as its main ingredient, this has not been the case with MOPPP, despite its similar potential for abuse.[6]

Chemistry

MOPPP is structurally related to α-PPP in the same way that PMA is related to amphetamine: a methoxy group has been added to the 4-position on the phenyl ring.

Comparison of similar molecular structure
MOPPP
α-PPP
PMA
Amphetamine

Metabolism

MOPPP appears to be metabolized within the liver chiefly by the enzyme CYP2D6.[2]

See also

References

  1. ↑ Springer D, Fritschi G, Maurer HH (August 2003). "Metabolism and toxicological detection of the new designer drug 4'-methoxy-alpha-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 793 (2): 331–42. doi:10.1016/S1570-0232(03)00334-9. PMID 12906908.
  2. 1 2 Springer D, Staack RF, Paul LD, Kraemer T, Maurer HH (October 2003). "Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 33 (10): 989–98. doi:10.1080/00498250310001602775. PMID 14555336. S2CID 7838464.
  3. ↑ Springer D, Fritschi G, Maurer HH (November 2003). "Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 796 (2): 253–66. doi:10.1016/j.jchromb.2003.07.008. PMID 14581066.
  4. ↑ Maurer HH, Kraemer T, Springer D, Staack RF (April 2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic Drug Monitoring. 26 (2): 127–31. doi:10.1097/00007691-200404000-00007. PMID 15228152. S2CID 9255084.
  5. ↑ Staack RF, Maurer HH (June 2005). "Metabolism of designer drugs of abuse". Current Drug Metabolism. 6 (3): 259–74. doi:10.2174/1389200054021825. PMID 15975043.
  6. ↑ "MDPV Bath Salts Drug Over The Counter". Healthbodydaily.com. 8 March 2011. Archived from the original on 10 March 2011.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.